Fig. 5
Treatment algorithm for patients with a) dyspnoea or b) exacerbations at review. aConsider if EOS ≥0.3 × 109 cells/L (≥300 cells/mm3) or EOS ≥0.1 × 109 cells/L (≥100 cells/mm3) AND ≥ 2 moderate exacerbations/1 hospitalisation. bConsider de-escalation of ICS or switch in response to pneumonia, inappropriate original indication or lack of response to ICS. Reproduced with permission from: Global Initiative for Chronic Obstructive Lung Disease 2021 Report; Figure 4.4. Available from https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.0-16Nov20_WMV.pdf, accessed 18 November 2020. EOS eosinophil count, FEV1 forced expiratory volume in 1 s, ICS inhaled corticosteroid, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist